RxDoctor Payments Data

Elie Mansour, MD

Adult Reconstructive Orthopaedic Surgery · New Haven, CTNPI 1831760164

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (49.1%), education and food and beverage — rather than concentrated in one kind of arrangement. 8 manufacturers reported payments, led by Smith+Nephew at 40.4% of the total. Reporting peaked in 2023 at $8,265 and has fallen 58.1% since, to $3,464 in 2025.

$23,613in general payments, 2019–2025

Across 122 payments — averaging $193.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Smith+Nephew$10K
  • Zimmer Biomet$6K
  • Stryker$6K
  • Arthrex$2K
  • Medical Device Business Services, Inc.$315
  • Davol Inc.$154
  • plus $161 from 2 others

What the payments were for

  • Travel & lodging$11,60049%
  • Food & beverage$5,81225%
  • Education$6,20026%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few adult reconstructive orthopaedic surgery providers in Connecticutto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$21,973
Medicare patients
40
Services billed
257

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Meloxicam22$13

Paid to pharmacies, not to this prescriber.

Other adult reconstructive orthopaedic surgery in New Haven

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →